Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Institute of Hematology and Blood Transfusion, Czech Republic
M.D. Anderson Cancer Center
Roswell Park Cancer Institute
BeOne Medicines
National Cancer Institute (NCI)
Chordia Therapeutics, Inc.
PedAL BCU, LLC
M.D. Anderson Cancer Center
Servier
Sumitomo Pharma America, Inc.
Curis, Inc.
M.D. Anderson Cancer Center
AstraZeneca
Thomas Jefferson University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Manchester
Disc Medicine, Inc
M.D. Anderson Cancer Center
Faron Pharmaceuticals Ltd
City of Hope Medical Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Southern California
University of Michigan Rogel Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Ciusss de L'Est de l'Île de Montréal
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Sanofi
University Hospital, Basel, Switzerland
National Institutes of Health Clinical Center (CC)
Fred Hutchinson Cancer Center
Incyte Corporation
M.D. Anderson Cancer Center
Incyte Corporation
Incyte Corporation
Rigel Pharmaceuticals
Ellipses Pharma
Constellation Pharmaceuticals
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Stanford University
Vor Biopharma
Haukeland University Hospital